Research programme: Avibody-based imaging agents - Avipep/SanofiAlternative Names: 89Zr-Avibodies
Latest Information Update: 13 Jul 2015
At a glance
- Originator Avipep
- Developer Avipep; Sanofi
- Class Imaging agents; Radiopharmaceutical diagnostics
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Unspecified
Most Recent Events
- 13 Jul 2015 Early research in Undefined indication (Diagnosis) in Australia (unspecified route)